Qifangfeixian granules

Small molecule

Qifangfeixian granules is one of 10 small molecule programs targeting Connective Tissue Disease. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Connective Tissue DiseaseActive, not recruiting

Connective Tissue DiseasePhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

10 competitors in Connective Tissue Disease

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

1 2

Benlysta

GGlaxo Dba Glaxosmithkline

Phase 3

2 3

Cytoxan

BBaxter Healthcare Corporation

Phase 3

1 4

Tetrandrine

PPeking University Third Hospital

Approved

1 5

Telitacicept

VVor Biopharma

Phase 2

1 6

Promacta

GSK

Preclinical

1 7

Gensci048

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 2

1 8

Ofev

Boehringer Ingelheim

Preclinical

1 9

CAR-T

HHebei Senlang Biotechnology Inc., Ltd.

Preclinical

1 10

Qifangfeixian granules

HHuilan Zhang

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2/3Recruiting

Connective Tissue Disease

NCT06674148

Clinical

Trials by Indication[1]

Connective Tissue Disease1 trial

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Qifangfeixian Granules in the Treatment of Connective Tissue Disease-Associated Interstitial Lung Disease (CTD-ILD)

Recruiting·HHuilan Zhang·Phase 2/3·NCT06674148·124 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Qifangfeixian granules. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Qifangfeixian granules compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Qifangfeixian granules. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Huilan Zhang company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: HHuilan Zhang

Qifangfeixian granules

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Connective Tissue Disease1 trial

References

Drug Info

Quick Facts

Related News